Hepatology International

, Volume 7, Issue 2, pp 508–515

Differences in the factors associated with serum viral load between genotypes 1 and 2 in patients with chronic hepatitis C

  • Shunsuke Sato
  • Takuya Genda
  • Katsuharu Hirano
  • Hironori Tsuzura
  • Yoshio Kanemitsu
  • Yutaka Narita
  • Tetsu Kikuchi
  • Katsuyori Ijima
  • Takafumi Ichida
Original Article

Abstract

Purpose

The serum hepatitis C virus (HCV) load is persistently stable in patients with untreated chronic hepatitis C, but its differences between individuals vary widely (above 4 logU/mL). Because serum viral load is an important factor for predicting clinical outcome of interferon-based antiviral therapy, this study was performed to clarify the factors associated with serum viral load in chronic hepatitis C patients.

Methods

We retrospectively analyzed data from 669 chronic hepatitis C patients with HCV genotype 1 or 2 infection. Stepwise regression analysis was used to estimate the relationship between demographic, viral, or biochemical variables and serum viral load.

Results

In univariate analysis, serum lipid profiles, such as total cholesterol, low-density lipoprotein (LDL) and triglyceride levels, and hemoglobin A1c (HbA1c) were correlated with the serum HCV viral load. In multivariate analysis, HCV genotype 1 infection and higher total cholesterol levels were associated with higher viral load. After stratification by HCV genotype, the serum viral load was associated with triglyceride and HbA1c in genotype 1 and with platelet counts and LDL in genotype 2. Histological data (413 patients) showed correlation between severe liver fibrosis and decreased serum viral load in patients with HCV genotype 2 but not genotype 1 infection.

Conclusions

These results suggest that viral kinetics is affected by different host factors for genotypes 1 and 2.

Keywords

Genotype Hepatitis C virus Low-density lipoprotein Triglyceride Viral load 

References

  1. 1.
    Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558–567PubMedCrossRefGoogle Scholar
  2. 2.
    Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: Projection to other countries in the foreseeable future. Oncology 2002;62(suppl 1):8–17PubMedCrossRefGoogle Scholar
  3. 3.
    Lau JY, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, Neuwald PD, Wilber JC. Significance of serum hepatitis C virus RNA in chronic hepatitis C. Lancet 1993;22:1351–1354Google Scholar
  4. 4.
    Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O’Grady J, Reichen J, Diago M, Lin A, Hofmann J, Brunda MJ. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666–1672PubMedCrossRefGoogle Scholar
  5. 5.
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958–965PubMedCrossRefGoogle Scholar
  6. 6.
    Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Günthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Müllhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY. Geneteic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338–1345PubMedCrossRefGoogle Scholar
  7. 7.
    Miham U, Herrmann E, Sarrazin C, Zeuzeum S. Review article: predicting response in hepatitis C virus therapy. Aliment Pharmacol Ther 2006;23:1043–1054CrossRefGoogle Scholar
  8. 8.
    Maekawa S, Enomoto N. Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. J Gastroenterol 2009;44:1009–1015PubMedCrossRefGoogle Scholar
  9. 9.
    Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeueum S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C: Randomized study of the effect of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346–355PubMedCrossRefGoogle Scholar
  10. 10.
    Iwasaki Y, Shiratori Y, Hige S, Nishiguchi S, Takagi H, Onji M, Yoshida H, Izumi N, Kohgo Y, Yamamoto K, Sato N, Shibuya A, Saito H, Sata M, Suzuki K, Kanaeko S, Moriyama M, Omata M. A randomized trial of 24 versus 48 weeks of peginterferon alpha-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan. Hepatol Int 2009;3:468–479PubMedCrossRefGoogle Scholar
  11. 11.
    Gordon SC, Dailey PJ, Silverman AL, Kahn BA, Kodali VP, Wilber JC. Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification. Hepatology 1998;28:1702–1706PubMedCrossRefGoogle Scholar
  12. 12.
    Yoshimura E, Hayashi J, Ueno K, Kishihara Y, Yamaji K, Etoh Y, Kashiwagi S. No significant changes in levels of hepatitis C virus (HCV) RNA by competitive polymerase chain reaction in blood samples from patients with chronic HCV infection. Dig Dis Sci 1997;42:772–777PubMedCrossRefGoogle Scholar
  13. 13.
    Ticehurst JR, Hamzeh FM, Thomas DL. Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis. J Clin Microbiol 2007;45:2426–2433PubMedCrossRefGoogle Scholar
  14. 14.
    Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, Brouwer JT, Chan SW, Chayama K, Chen DS, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994;19(suppl):1321–1324PubMedCrossRefGoogle Scholar
  15. 15.
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513–1520PubMedCrossRefGoogle Scholar
  16. 16.
    Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001;96:3142–3146PubMedCrossRefGoogle Scholar
  17. 17.
    Ye J, Wang C, Sumpter R Jr, Brown MS, Goldstein JL, Gale M Jr. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci USA 2003;100:15865–15870PubMedCrossRefGoogle Scholar
  18. 18.
    Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 2005;102:2561–2566PubMedCrossRefGoogle Scholar
  19. 19.
    Egger D, Wölk B, Gosert R, Bianchi L, Blum HE, Moradpour D, Bienz K. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 2002;76:5974–5984PubMedCrossRefGoogle Scholar
  20. 20.
    Lundin M, Monné M, Widell A, Von Heijne G, Persson MA. Topology of the membrane-associated hepatitis C virus protein NS4B. J Virol 2003;77:5428–5438PubMedCrossRefGoogle Scholar
  21. 21.
    Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, Bartenschlager R, Wakita T, Hijikata M, Shimotohno K. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007;9:1089–1097PubMedCrossRefGoogle Scholar
  22. 22.
    McLauchlan J. Hepatitis C virus: viral proteins on the move. Biochem Soc Trans 2009;37:986–990PubMedCrossRefGoogle Scholar
  23. 23.
    Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999;96:12766–12771PubMedCrossRefGoogle Scholar
  24. 24.
    Burlone ME, Budkowska A. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J Gen Virol 2009;90:1055–1070PubMedCrossRefGoogle Scholar
  25. 25.
    Barth H, Liang TJ, Baumert TF. Hepatitis C virus entry: molecular biology and clinical implications. Hepatology 2006;44:527–535PubMedCrossRefGoogle Scholar
  26. 26.
    Maggi G, Bottelli R, Gola D, Perricone G, Posca M, Zavaglia C, Odeo G. Serum cholesterol and chronic hepatitis C. Ital J Gastroenterol 1996;28:436–440PubMedGoogle Scholar
  27. 27.
    Fabris C, Federico E, Soardo G, Falleti E, Pirisi M. Blood lipids of patients with chronic hepatitis: differences related to viral etiology. Clin Chim Acta 1997;261:159–165PubMedCrossRefGoogle Scholar
  28. 28.
    Moriya K, Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Yotsuyanagi H, Iino S, Kimura S, Koike K. Serum lipid profile of patients with genotype 1b hepatitis C viral infection in Japan. Hepatol Res 2003;25:371–376PubMedCrossRefGoogle Scholar
  29. 29.
    Siagris D, Christofidou M, Theocharis GJ, Pagoni N, Papadimitriou C, Lekkou A, Thomopoulos K, Starakis I, Tsamandas AC, Labropoulou-Karatza C. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat 2006;13:56–61PubMedCrossRefGoogle Scholar
  30. 30.
    Hsu CS, Liu CH, Liu CJ, Wang CC, Chen CL, Lai MY, Chen PJ, Chen DS, Kao JH. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection. Am J Gastroenterol 2009;104:598–604PubMedCrossRefGoogle Scholar
  31. 31.
    Hayashi J, Kishihara Y, Yoshimura E, Tani Y, Yamaji K, Ikematsu H, Ishiko H, Kashiwagi S. Relationship of genotype to level of hepatitis C viraemia determined by competitive polymerase chain reaction. J Infect 1995;30:235–239PubMedCrossRefGoogle Scholar
  32. 32.
    Tanaka K, Hirohata T. Relationship of hepatitis C genotypes and viremia levels with development of hepatocellular carcinoma among Japanese. Fukuoka Igaku Zasshi 1998;89:238–248PubMedGoogle Scholar
  33. 33.
    Berger A, von Depka Prondzinski M, Doerr HW, Rabenau H, Weber B. Hepatitis C plasma load is associated with HCV genotype but not with HIV coinfection. J Med Virol 1996;48:339–343PubMedCrossRefGoogle Scholar
  34. 34.
    Huang H, Sun F, Owen DM, Li W, Chen Y. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci USA 2007;104:5848–5853PubMedCrossRefGoogle Scholar
  35. 35.
    Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A, Suchindran S, Muir AJ, Guyton JR, Gardner SD, McHutchison JG, McCarthy JJ. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 2010;51:1904–1911PubMedCrossRefGoogle Scholar
  36. 36.
    Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, Hong L, McKenzie A, Patel K, Shianna KV, McHutchison JG, Goldstein DB, Afdhal N. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010;52:1888–1896PubMedCrossRefGoogle Scholar
  37. 37.
    Duvoux C, Pawlotsky JM, Bastie A, Cherqui D, Soussy CJ, Dhumeaux D. Low HCV replication levels in end-stage hepatitis C virus-related liver disease. J Hepatol 1999;31:593–597PubMedCrossRefGoogle Scholar
  38. 38.
    Fanning L, Kenny E, Sheehan M, Cannon B, Whelton M, O’Connell J, Collins JK, Shanahan F. Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogenous patient population. Hepatology 1999;29:904–907PubMedCrossRefGoogle Scholar

Copyright information

© Asian Pacific Association for the Study of the Liver 2011

Authors and Affiliations

  • Shunsuke Sato
    • 1
  • Takuya Genda
    • 1
  • Katsuharu Hirano
    • 1
  • Hironori Tsuzura
    • 1
  • Yoshio Kanemitsu
    • 1
  • Yutaka Narita
    • 1
  • Tetsu Kikuchi
    • 1
  • Katsuyori Ijima
    • 1
  • Takafumi Ichida
    • 1
  1. 1.Department of Gastroenterology and HepatologyJuntendo University Shizuoka HospitalShizuokaJapan

Personalised recommendations